Wed, 27 Jun 2018
Fostera® Gold PCV provides broadest antigenic coverage against evolving virus
Zoetis has received approval from the U.S. Department of Agriculture to begin marketing Fostera® Gold PCV, the pork industry’s first monovalent vaccine for swine that includes two genotypes of porcine circovirus type 2 (PCV2) — 2a and 2b.
The new vaccine follows the March 2018 launch of Fostera® Gold PCV MH, which contains the same two PCV genotypes, but also protects against Mycoplasma hyopneumoniae (M. hyo).
“Our new monovalent PCV vaccine, Fostera Gold PCV, is ideal for genetic-nucleus and multiplier herds that must show proof they are negative for M. hyo and cannot have circulating M. hyo antibodies,” said Lucina Galina, DVM, PhD, director, swine technical services, Zoetis.
The veterinarian said some commercial farms that have eliminated M. hyo may want to consider the monovalent vaccine if they are located in isolated areas with a low risk of mycoplasma reinfection. However, most operations would benefit from using Fostera Gold PCV MH since they are located in pig-dense areas.
Because they contain PCV2a and 2b genotypes, the latter one being a genotype closely genetically related to PCV2d, the two new PCV vaccines from Zoetis should provide the broadest range of antigenic coverage against evolving PCV2 viruses in U.S. swine herds.
The most prevalent PCV2 genotypes currently circulating in U.S. herds are PCV2d followed by PCV2b and PCV2a, according to the latest data from Iowa State University’s Veterinary Diagnostic Lab. Other commercial PCV2 vaccines contain either the PCV2a or PCV2b genotype, but not both. Although they have provided acceptable cross protection against 2d in many herds, it has sometimes been insufficient, Dr. Galina said.
The duration of immunity (DOI) with Fostera Gold PCV is at least 23 weeks for PCV, which means the vaccine will protect most herds through the finishing period. Fostera Gold PCV MH has also been shown to provide a minimum of 23 weeks of protection against M. hyo.
Both vaccines may be administered as a single, 2-ml dose from 3 weeks of age or as a split dose with two, 1-ml doses administered 3 weeks apart. The split-dose regimen can be initiated as early as 3 days of age, but Dr. Galina recommends using either one dose from 3 weeks of age or the two-dose regimen starting at 3 weeks of age.
In a field trial involving 880 pigs, the efficacy of the two PCV2 genotypes in both vaccines was demonstrated based on viremia, the presence of lung lesions and immunohistochemistry — a process that shows how antibodies bind to antigens. The vaccine also has a high margin of safety, Galina reported.
For more information on Fostera Gold PCV and Fostera Gold PCV MH, veterinarians and producers should contact their Zoetis representative or visit www.zoetisUS.com/FosteraGold.
Zoetis (NYSE: ZTS) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.